Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Soliris Biosimilars Edge Closer In Brazil

Executive Summary

Court’s “mailbox” patent decision opens door to competition for Alexion’s Soliris in Brazil.

You may also be interested in...



Alexion Gets Speedy Review For Soliris Successor

Switching patients from the very expensive ultra rare disorder drug to ravulizumab will be a key strategy for Alexion if the latter is approved. Recent compelling data in paroxysmal nocturnal hemoglobinuria patients suggests the long-acting C5 complement inhibitor could offer more benefit than its predecessor with more convenient dosing.

England’s Innovative Medicines Fund To Put Spotlight On Rare Disease Treatments

While the much-anticipated Innovative Medicines Fund is likely to benefit rare diseases in particular, other products must gain too.

ATMP Withdrawals Are Keeping EU Regulators Awake At Night

Europe is becoming less competitive in the advanced therapy space, something that is reflected in the number of EU ATMP marketing authorization withdrawals, speakers said at an event organized by the Alliance for Regenerative Medicine.

Topics

UsernamePublicRestriction

Register

PS123030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel